#USA #Washington, D.C. #Lakewood-Amedex #antimicrobial #Nu-3

Lakewood-Amedex Biotherapeutics Reveals Groundbreaking Data on Nu-3's Antimicrobial Efficacy at IDWeek 2026

Lakewood-Amedex Biotherapeutics Presents Nu-3's Efficacy

Lakewood-Amedex Biotherapeutics Inc., a clinical-stage biotechnology firm, recently shared significant findings regarding its lead antimicrobial candidate, Nu-3, at IDWeek 2026 in Washington, D.C. This event, which took place from October 21-24, highlighted Nu-3 as a potential game-changer in combating resistant bacterial infections, particularly in the context of diabetic foot ulcers.

Key Findings of Nu-3

The poster presentation titled "Nu-3 – A Novel, Broad Spectrum Antimicrobial Compound with High In-Vitro Activity Against Resistant Pathogens for the Treatment of Infected Diabetic Foot Ulcers," focused on Nu-3's impressive antimicrobial properties. The research demonstrated that Nu-3 exhibits broad-spectrum activity against various Gram-positive and Gram-negative bacteria, including multidrug-resistant strains. Notably, the compound was found to rapidly eradicate tested bacterial pathogens within minutes, showcasing a potential for effective treatment in clinical settings.

Additionally, Nu-3 has displayed efficacy against biofilm-forming organisms, which are notoriously difficult to treat. This is particularly significant for diabetic foot ulcers, where infections often become complicated due to biofilms.

Resistance Profile

The researchers also conducted serial-passage testing, which is crucial for gauging the potential for bacterial resistance to develop against a new antimicrobial agent. Findings indicated that Nu-3 has a favorable resistance profile, showing only a slight elevation in minimum inhibitory concentration (MIC) values for critical pathogens like Staphylococcus aureus and Escherichia coli. In stark contrast, traditional antibiotics such as ciprofloxacin exhibited a dramatic rise in MIC values, ranging from 600 to 2,000-fold, signaling a rising concern over their efficacy in treating resistant infections.

The Importance of Addressing Antimicrobial Resistance

According to Kelvin Cooper, CEO of Lakewood-Amedex, these findings reinforce the vital role Nu-3 could play in addressing the pressing challenge of antimicrobial resistance. With around half of diabetic foot ulcers becoming infected and a significant proportion caused by resistant organisms—most notably methicillin-resistant Staphylococcus aureus (MRSA)—the need for effective treatment options is paramount.

Currently, Nu-3 is being evaluated in a Phase 2a clinical trial involving patients with mildly infected diabetic foot ulcers, with preliminary data expected in early 2027. If successful, this could lead to Nu-3 being positioned as a differentiated therapy for problematic infections.

Conclusion

The presentation of Nu-3's compelling data at IDWeek 2026 underscores the urgent need for innovative antimicrobial solutions in an era where resistant infections are on the rise. As Lakewood-Amedex Biotherapeutics continues its clinical development journey, the hopes are high for Nu-3 to emerge as a significant new treatment in the battle against antibiotic resistance, providing hope to patients with limited options for managing infected diabetic foot ulcers. For further developments, visit Lakewood-Amedex's official website.